• Bloom Health Partners has announced a non-brokered private placement for gross proceeds of up to $2 million
  • The company will issue up to 10 million units priced at $0.20 per unit
  • Net proceeds will be used for ongoing working capital and corporate development
  • Bloom Health Partners is a global platform for healthcare security, diagnostic testing and occupational health-tech
  • Bloom Health Partners Inc. (BLMH) opened trading at C$0.27

Bloom Health Partners (BLMH) has announced a non-brokered private placement for gross proceeds of up to $2 million.

The company will issue up to 10 million units priced at $0.20 per unit. The units are comprised of one common share and one-half of one transferable common share purchase warrant. Each whole warrant will entitle the holder to acquire one additional common share at a price of $0.30 for 12 months following the offering.

Net proceeds will be used for ongoing working capital and corporate development.

The offering is expected to close on or about June 22, 2022 and is subject to the receipt of all necessary regulatory and stock exchange approvals.

Bloom Health Partners is a global platform for healthcare security, diagnostic testing and occupational health-tech. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety.

Bloom Health Partners Inc. (BLMH) opened trading at C$0.27.

More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.